A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)

Protocol No

BMS-CA0561060

Phase

III

Summary

This project is being done to learn more about Luspatercept if administrated at the maximum approved starting dose to assess that a quicker benefit can be seen in your transfusion burden and hemoglobin level.

Description

This project is being done to learn more about Luspatercept if administrated at the maximum approved starting dose to assess that a quicker benefit can be seen in your transfusion burden and hemoglobin level.

Status

SRC APPROVAL